McKesson (MCK) Stock May Trade At A Discount As Cash Flow Holds Up
McKesson stock has delivered a very strong 336.0% return over the past five years, yet the current valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) model both still point to the shares trading below their estimated worth. Over 5 years, McKesson has returned 336.0%, which puts recent share price moves in the context of a long and very strong run. Expectations for McKesson's ability to keep converting revenue into reliable cash flows can support the...
Yahoo14 days agoMCK
McKesson (MCK) Joined A Tech Summit, Is It Still 13% Undervalued?
McKesson (MCK) is in focus after its technology leadership team joined the 17th Annual Atlanta C-Level Technology Leadership Summit, highlighting how its healthcare technology services fit alongside recent quarterly results and the current stock performance. See our latest analysis for McKesson. At a share price of $853.71, McKesson has eased slightly in the very short term, with a 1-day share price return that declined 1.79% and a 7-day share price return that declined 2.85%. However, its...
Yahoo14 days agoMCK
RBC Capital Initiates Coverage of McKesson (MCK) with Sector Perform Recommendation
Fintel15 days agoMCK
Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?
Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.
Yahoo16 days agoMCK
Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls
Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls
Yahoo16 days agoMCK
Winners And Losers Of Q2: McKesson (NYSE:MCK) Vs The Rest Of The Healthcare Providers & Services Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how healthcare providers & services stocks fared in Q2, starting with McKesson (NYSE:MCK).
Yahoo16 days agoMCK
Barclays Maintains Overweight on McKesson, Raises Price Target to $1000
Barclays analyst Glen Santangelo maintains McKesson (NYSE:MCK) with a Overweight and raises the price target from $925 to $1000.
Benzinga16 days agoMCK
RBC Capital Initiates Coverage On McKesson with Sector Perform Rating, Announces Price Target of $845
RBC Capital analyst Ryan Halsted initiates coverage on McKesson (NYSE:MCK) with a Sector Perform rating and announces Price Target of $845.
Benzinga16 days agoMCK
AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.
Yahoo23 days agoMCK
Cardinal Health Q4 Earnings Call Highlights
Cardinal Health (NYSE:CAH) reported fourth-quarter fiscal 2026 results marked by growth in revenue, operating earnings and adjusted earnings per share, supported by demand in its pharmaceutical and specialty businesses and a one-time tariff-related benefit in its medical products segment. For the q
Yahoo24 days agoMCK
S&P 500 Medical Stocks: Three Trade Near Buy Points; One Rallies Despite Mixed Results
S&P 500 drug distributor Cardinal Health easily topped fiscal fourth-quarter earnings forecasts despite a revenue shortfall. Rival McKesson, which whipsawed after its earnings report last week, has climbed back near a buy point. Cencora, another big S&P 500 drug distributor, also is near a buy point, but MCK stock may be the strongest of the three.
Yahoo24 days agoMCK